Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program
14 6월 2023 - 8:30PM
Immix Biopharma, Inc., (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We”
or “Us”), a biopharmaceutical company pioneering CAR-T cell
therapies and tissue specific therapeutics targeting oncology and
immuno-dysregulated diseases, today announced that it has completed
its previously announced “at-the-market” equity offering program
(the “ATM Offering”).
“We are delighted to complete the $5 million common stock ATM
offering. We believe the terms were favorable to investors in
a turbulent market environment. Further, we would like to
welcome Bridgewest to our institutional investor syndicate.
We are focused on continued efficient execution of our
clinical development plans: NEXICART-1 for NXC-201, which we
believe is the world’s first out-patient CAR-T in multiple myeloma
and AL amyloidosis, and our IMX-110 clinical trials including
IMMINENT-01 combination trial with BeiGene’s anti-PD-1 antibody,”
said Ilya Rachman, MD PhD, Chief Executive Officer, Immix
Biopharma.
ImmixBio disclosed on March 22, 2023 that it filed a prospectus
supplement with the U.S. Securities and Exchange Commission to
offer and sell shares of the Company’s common stock having an
aggregate offering price of up to $5,000,000 from time to time
through the ATM Offering. The Company ultimately sold 2,263,868
shares of common stock and generated aggregate gross proceeds
before commissions and offering expenses of approximately
$5,000,000. ThinkEquity acted as agent for the ATM.
The Company intends to use net proceeds from the ATM Offering
for its IMX-110 + tislelizumab Phase 1b combination clinical trial,
its IMX-110 monotherapy clinical trial, and general corporate
purposes.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a
clinical-stage biopharmaceutical company pioneering a novel class
of CAR-T cell therapies and Tissue-Specific Therapeutics (TSTx)
targeting oncology and immuno-dysregulated diseases with >75
patients treated to-date. Our lead cell therapy asset is NXC-201 in
multiple myeloma and AL Amyloidosis, which we believe could be the
world’s first out-patient CAR-T. Our lead TSTx asset IMX-110,
currently in Phase 1b/2a clinical trials as a monotherapy and
IMMINENT-01 combination clinical trial with BeiGene’s anti-PD-1
antibody tislelizumab, holds Orphan Drug Designation (ODD) and Rare
Pediatric Disease Designation (RPDD) by the FDA. ImmixBio
subsidiary Nexcella, Inc develops CAR-T NXC-201 for multiple
myeloma and AL amyloidosis, with 92% and 100% response rates in
each indication, respectively, as of February 9, 2023, currently
being trialed in NEXICART-1. Learn more at www.immixbio.com.
Forward Looking Statements
This press release contains “forward-looking statements”
Forward-looking statements reflect our current view about future
events. When used in this press release, the words “anticipate,”
“believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the
negative of these terms and similar expressions, as they relate to
us or our management, identify forward-looking statements. Such
statements, include, but are not limited to, statements contained
in this press release relating to our business strategy, our future
operating results and liquidity and capital resources outlook.
Forward-looking statements are based on our current expectations
and assumptions regarding our business, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict. Our actual
results may differ materially from those contemplated by the
forward-looking statements. They are neither statements of
historical fact nor guarantees of assurance of future performance.
We caution you therefore against relying on any of these
forward-looking statements. Important factors that could cause
actual results to differ materially from those in the
forward-looking statements include, without limitation, our ability
to raise capital to fund continuing operations; our ability to
protect our intellectual property rights; the impact of any
infringement actions or other litigation brought against us;
competition from other providers and products; our ability to
develop and commercialize products and services; changes in
government regulation; our ability to complete capital raising
transactions; and other factors relating to our industry, our
operations and results of operations. Actual results may differ
significantly from those anticipated, believed, estimated,
expected, intended or planned including: the uncertainties related
to market conditions and other factors described more fully in the
section entitled ‘Risk Factors’ in Immix Biopharma’s Annual Report
on Form 10-K for the year ended December 31, 2022, and other
periodic reports filed with the Securities and Exchange Commission.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and Immix Biopharma, Inc.
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Factors or events that could cause our actual results to differ
may emerge from time to time, and it is not possible for us to
predict all of them. We cannot guarantee future results, levels of
activity, performance or achievements.
Contacts:
Stern Investor RelationsSuzanne MessereManaging
DirectorSuzanne.Messere@sternir.com
Company Contact:
irteam@immixbio.com
Immix Biopharma (NASDAQ:IMMX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Immix Biopharma (NASDAQ:IMMX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024